Effectiveness of Oral Semaglutide in Management of Type 2 Diabetes: A Real-World Study from India
Introduction: Oral Semaglutide (Sema-o) is the first oral glucagon like peptide-1 receptor analogue (GLP-1RA) commercially available for the treatment of type 2 diabetes (T2D). This study aimed to evaluate the efficacy of Sema-o in patients with T2D when added to the existing therapy. Methods: This...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2024-12-01
|
| Series: | Indian Journal of Endocrinology and Metabolism |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/ijem.ijem_266_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841553107554664448 |
|---|---|
| author | Aditya Dutta Shama Mahendru Rutuja Sharma Ambrish Mithal |
| author_facet | Aditya Dutta Shama Mahendru Rutuja Sharma Ambrish Mithal |
| author_sort | Aditya Dutta |
| collection | DOAJ |
| description | Introduction:
Oral Semaglutide (Sema-o) is the first oral glucagon like peptide-1 receptor analogue (GLP-1RA) commercially available for the treatment of type 2 diabetes (T2D). This study aimed to evaluate the efficacy of Sema-o in patients with T2D when added to the existing therapy.
Methods:
This retrospective real-world study enrolled adult patients with diabetes taking Sema-o, with at least one follow-up (from February 2022 till October 2023). A proforma recorded baseline and follow-up date, medications, body composition, laboratory and clinical parameters. Data is presented as median (interquartile range) and was analysed using SPSS.
Results:
A total of 351 patients followed up once, while 56 patients had 4 follow-up visits. Baseline parameters were as follows: age 53 years (43–61), duration of diabetes 10 years (5–16), weight 91 kg (79–103), body mass index (BMI) 32.7 kg/m2 (29.3–36.6) and HbA1c 7.9% (6.9–9). The addition of Sema-o in the existing therapy for diabetes resulted in a significant reduction in HbA1c {follow-up: 1st 0.5%, 2nd 0.9%, 3rd 1.1% and 4th 1.1% (all, P < 0.001)} and % weight reduction {follow-up: 1st 2%, 2nd 3.3%, 3rd 4.1% and 4th 4.3% (all, P < 0.001)} from baseline. Reductions in BMI, glucose (fasting/post-prandial), lipids, liver enzymes and body composition parameters were significant. Gastro-intestinal side-effects (299 events in 52.4% of patients) were frequent. A total of 34/9.7% patients discontinued Sema-o.
Conclusion:
Intensification of existing therapy with Sema-o in obese patients with moderately uncontrolled diabetes proved to be an effective and relatively safe strategy. Achieving normoglycemia and reductions in weight, lipids and body fat/visceral fat with Sema-o may confer a much needed cardiometabolic benefit in these patients. |
| format | Article |
| id | doaj-art-7a0faa326eae4e9788e08b9ed77ff21c |
| institution | Kabale University |
| issn | 2230-8210 2230-9500 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Endocrinology and Metabolism |
| spelling | doaj-art-7a0faa326eae4e9788e08b9ed77ff21c2025-01-09T12:24:27ZengWolters Kluwer Medknow PublicationsIndian Journal of Endocrinology and Metabolism2230-82102230-95002024-12-0128665365810.4103/ijem.ijem_266_24Effectiveness of Oral Semaglutide in Management of Type 2 Diabetes: A Real-World Study from IndiaAditya DuttaShama MahendruRutuja SharmaAmbrish MithalIntroduction: Oral Semaglutide (Sema-o) is the first oral glucagon like peptide-1 receptor analogue (GLP-1RA) commercially available for the treatment of type 2 diabetes (T2D). This study aimed to evaluate the efficacy of Sema-o in patients with T2D when added to the existing therapy. Methods: This retrospective real-world study enrolled adult patients with diabetes taking Sema-o, with at least one follow-up (from February 2022 till October 2023). A proforma recorded baseline and follow-up date, medications, body composition, laboratory and clinical parameters. Data is presented as median (interquartile range) and was analysed using SPSS. Results: A total of 351 patients followed up once, while 56 patients had 4 follow-up visits. Baseline parameters were as follows: age 53 years (43–61), duration of diabetes 10 years (5–16), weight 91 kg (79–103), body mass index (BMI) 32.7 kg/m2 (29.3–36.6) and HbA1c 7.9% (6.9–9). The addition of Sema-o in the existing therapy for diabetes resulted in a significant reduction in HbA1c {follow-up: 1st 0.5%, 2nd 0.9%, 3rd 1.1% and 4th 1.1% (all, P < 0.001)} and % weight reduction {follow-up: 1st 2%, 2nd 3.3%, 3rd 4.1% and 4th 4.3% (all, P < 0.001)} from baseline. Reductions in BMI, glucose (fasting/post-prandial), lipids, liver enzymes and body composition parameters were significant. Gastro-intestinal side-effects (299 events in 52.4% of patients) were frequent. A total of 34/9.7% patients discontinued Sema-o. Conclusion: Intensification of existing therapy with Sema-o in obese patients with moderately uncontrolled diabetes proved to be an effective and relatively safe strategy. Achieving normoglycemia and reductions in weight, lipids and body fat/visceral fat with Sema-o may confer a much needed cardiometabolic benefit in these patients.https://journals.lww.com/10.4103/ijem.ijem_266_24hba1coral semaglutidetype 2 diabetesweight loss |
| spellingShingle | Aditya Dutta Shama Mahendru Rutuja Sharma Ambrish Mithal Effectiveness of Oral Semaglutide in Management of Type 2 Diabetes: A Real-World Study from India Indian Journal of Endocrinology and Metabolism hba1c oral semaglutide type 2 diabetes weight loss |
| title | Effectiveness of Oral Semaglutide in Management of Type 2 Diabetes: A Real-World Study from India |
| title_full | Effectiveness of Oral Semaglutide in Management of Type 2 Diabetes: A Real-World Study from India |
| title_fullStr | Effectiveness of Oral Semaglutide in Management of Type 2 Diabetes: A Real-World Study from India |
| title_full_unstemmed | Effectiveness of Oral Semaglutide in Management of Type 2 Diabetes: A Real-World Study from India |
| title_short | Effectiveness of Oral Semaglutide in Management of Type 2 Diabetes: A Real-World Study from India |
| title_sort | effectiveness of oral semaglutide in management of type 2 diabetes a real world study from india |
| topic | hba1c oral semaglutide type 2 diabetes weight loss |
| url | https://journals.lww.com/10.4103/ijem.ijem_266_24 |
| work_keys_str_mv | AT adityadutta effectivenessoforalsemaglutideinmanagementoftype2diabetesarealworldstudyfromindia AT shamamahendru effectivenessoforalsemaglutideinmanagementoftype2diabetesarealworldstudyfromindia AT rutujasharma effectivenessoforalsemaglutideinmanagementoftype2diabetesarealworldstudyfromindia AT ambrishmithal effectivenessoforalsemaglutideinmanagementoftype2diabetesarealworldstudyfromindia |